SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative…
MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company…
September 09, 2025 13:19 ET | Source: Booking Health Langenfeld, Germany, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Booking Health, a…
This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective…
RIYADH, Saudi Arabia, Aug. 30, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC), ranked 15th globally…
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial…
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to…
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly…
July 25, 2025 16:05 ET | Source: atai Life Sciences Initial results demonstrate numerical improvement of cognitive and functional measures…